



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/645,811	08/21/2003	Christopher Marrs	NEU-5009 8041 EXAMINER		
27777	7590 03/18/2005				
PHILIP S. JOHNSON JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA			MAYER, SUZANNE MARIE		
			ART UNIT	PAPER NUMBER	
	ISWICK, NJ 08933-7003		1653	1653	
			DATE MAILED: 03/18/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/645,811	MARRS, CHRISTOPHER	
Office Action Summary	Examiner	Art Unit	
	Suzanne M. Mayer, Ph.D.	1653	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be followed by within the statutory minimum of thirty (30) do will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	timely filed ays will be considered timely. m the mailing date of this communication. IED (35 U.S.C. § 133).	
Status		•	
 1) Responsive to communication(s) filed on 12 J 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowated closed in accordance with the practice under I 	s action is non-final. Ince except for formal matters, p		
Disposition of Claims			
 4) Claim(s) 1-32 is/are pending in the application 4a) Of the above claim(s) 17-32 is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1-16 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or are subject to restriction and/or are subject. 	wn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicated any not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 10.	cepted or b) objected to by the drawing(s) be held in abeyance. Setion is required if the drawing(s) is c	ee 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat* See the attached detailed Office action for a list	ts have been received. ts have been received in Applica ority documents have been recei au (PCT Rule 17.2(a)).	ation No ved in this National Stage	
 Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date S. Patent and Trademark Office 	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:	• •	

DETAILED ACTION

Status of the Claims

1. Newly submitted claims 17-32 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: the methods for topical application of a composition with an oxygen labile active agent to the skin or hair, recited in claims 17-32, could be practiced with another materially different product than the composition of claims 1-16, and thus the method claims are patentably distinct from the product claims.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 17-32 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

2. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Art Unit: 1653

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Response to Claim Amendments and Remarks

3. The Examiner acknowledges the amendment to the claims filed on January 12, 2005. However, the examiner does not find Applicants arguments persuasive to overcome the original prior art rejections because the mere introduction of the intended

Art Unit: 1653.

use language recited in the pre-amble does not hold any definitive patentable weight as the preamble in the instant case does not breathe life and meaning into the claims. See for example, Corning Glass Works, 868 F.2d at 1257, 9 USPQ2d at 1966. If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention's limitations, then the preamble is not considered a limitation and is of no significance to claim construction. Pitney Bowes, Inc. v. Hewlett-Packard Co., 182 F.3d 1298, 1305, 51 USPQ2d 1161, 1165 (Fed. Cir. 1999). See also *Rowe v. Dror*, 112 F.3d 473, 478, 42 USPQ2d 1550, 1553 (Fed. Cir. 1997) ("where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation"). Even if the preamble were given patentable weight in the instant case, Ferruzzi et al. (US 2004/0096547) would still meet the limitations of the composition and the preamble because when an individual drinks the energy drink of Ferruzzi et al., the drink will come into contact with a persons upper lips (skin) and hair of the upper lip. Additionally, even though Furruzzi et al., Jung et al. and Wang et al. do not suggest their compositions to be used for topical administration to the skin or hair, this limitation does not ultimately change the composition as claimed and the thus composition is still anticipated.

Art Unit: 1653

Claim Rejections - 35 USC § 102 - Necessitated By Amendment

4. Claims 1-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Collins et al. Collins et al. teach a topical composition comprising whey protein (which contains lactoglobulin) and Vitamins A, E and C (for clearly defined synonyms and their references of these, see paragraph 4, 2nd paragraph from the Office Action dated 03 September 2004 OR see column 3 lines 60-67 through column 4, lines 1-29) in amounts which are equivalent to those stated in claims 5 and 9 (see claims 1-12). Thus the claims have been anticipated.

Conclusion

- 5. No claim is allowed.
- 6. Applicant's amendment necessitated the new grounds of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1653

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzanne M. Mayer, Ph.D. whose telephone number is 571-272-2924. The examiner can normally be reached on Monday to Friday, 8.30am to 5.00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SMM

09 March 2005

JON WEBER

SUPERVISORY PATENT EXAMINER